This mdr is being submitted due to the reported fascial dehiscence with bowel obstruction requiring emergent surgery and hospitalization.
Upon exploration for management of the event, it was the operating surgeon's opinion that the fascial dehiscence was not the result of acell device failure; that the device performed as expected, that the fascial dehiscence was, in fact, the primary event and that the event resulted from patient factors and inherent patient comorbidities.
The acell device was explanted and discarded by the hospital, it is not available for evaluation.
A review of the manufacturing records for this lot identified no deviations in the production process.
The device was manufactured and distributed sterile in compliance with fda, state, local laws and regulations, and acell's operating procedures.
Acell conducted suture retention testing on the same retained lot which met specification.
|
On (b)(6) 2019, acell, inc.
Was notified by a surgeon that a patient had a fascial dehiscence with bowel obstruction requiring emergent surgery and hospitalization on (b)(6) 2019.
The surgeon observed that the primary sutures used to close the defect had ruptured along with the implanted acell device which had been placed as an underlay.
The surgeon informed acell that the patient had been non-complaint with post-operative activity instructions.
The surgeon explanted and discarded the acell device.
The subsequent repair was completed with a non-acell device, a synthetic mesh.
There was no infection present after acell implantation or at acell explantation.
The patient developed an infection after implantation of the synthetic mesh.
|